 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...3536373839404142434445...4748» |
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - May 27, 2020
P3, N=332, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Emerging therapies for small cell lung cancer. (Pubmed Central) - May 17, 2020
Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Anlotinib inhibits the progress of colorectal cancer cells by antagonizing glycolysis & JAK2-STAT3 signaling (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3825;
Our preclinical studies showed that anlotinib inhibited cell proliferation, invasion, migration & activated apoptosis by antagonizing glycolysis & JAK2-STAT3 signaling. Combination chemotherapy of anlotinib with cisplatin is more sensitive to CRC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. (Pubmed Central) - May 15, 2020
Combination chemotherapy of anlotinib with cisplatin is more sensitive to CRC. This study suggested that CXCL2 is involved in anlotinib resistance in NCI-H1975 cells and provided an insight for understanding the resistant mechanism of anlotinib.
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Metastases: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 12, 2020
P3, N=528, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical: .@StephenVLiu of @MedStarGUH discusses the promise of anlotinib in previously treated patients with small cell lung cancer and other emerging agents in the space. Watch the full clip here: https://t.co/rwaQDrlr69 #lcsm (Twitter) - May 7, 2020
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical, Ofev (nintedanib) / Boehringer Ingelheim
Journal, IO Biomarker: Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. (Pubmed Central) - May 6, 2020
However, the lack of predictive biomarkers of response has limited the development of this class of drugs in NSCLC. Combination trials with chemotherapy, immunotherapy or other targeted drugs are ongoing, and while some have already confirmed the role of antiangiogenic small molecules in integrated regimes, others are still evaluating the efficacy of these drugs and raising questions about their cost and tolerability.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
New P2 trial, Combination therapy: ANNIE: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - May 6, 2020
P2, N=40, Recruiting, Sponsor: Jihong Liu
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5898;
P2/3
In patients receiving anlotinib, longer mPFS was observed in patients of age > 40 y, ECOG PS = 1 and female. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5884;
P2/3
In this retrospective analyses, TSH increased, hypertriglyceridemia and proteinuria can serve as biomarkers in aSTS patients treated with anlotinib. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical, docetaxel / Generic mfg.
[VIRTUAL] A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5646;
P2
It will be further explored in a randomized phase III trial. Research Funding: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with poor performance status after second or more -line treatment. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5608;
SqCLC patients with higher PS scores still benefit from anlotinib and S-1 combination regimen, even after they failed second-line or above systemic treatment. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5431;
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5430;
- pemetrexed / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] APC fusions analysis in Chinese non-small cell lung cancer (NSCLC) using comprehensive NGS panel: A multicenter study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5411;
NGS can identify novel fusions and increase the list of actionable variants for patients. More patients can benefit from targeted treatment.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): A subgroup analysis based on the ALTER01031 trial. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4647;
P2/3
A possible positive association was also observed between dose reductions and better clinical outcomes. Research Funding: None
- pemetrexed / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4595;
Anlotinib (AL3818) plus pemetrexed showed a promising activity with an acceptable safety profile for previously platinum-treated patients with recurrent advanced epithelial ovarian cancer. Research Funding: Beijing Medical and Health Found, Pharmaceutical/Biotech Company
- Recentin (cediranib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] A phase II study of anlotinib with cediranib as a second-line treatment for patients with advanced biliary tract cancers (aBTCs). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4186;
Updated data, including safety, efficacy, and biomarkers will be presented. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Efficacy and safety of anlotinib combined with transarterial chemoembolization versus transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma: A retrospective study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4085;
It still needs more further randomized controlled trials to clarify the potential role of Anlotinib in hepatocellular carcinoma. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical, irinotecan / Generic mfg.
[VIRTUAL] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3862;
The combination of anlotinib and irinotecan had promising anti-tumor activity in the second-line treatment of advanced CRC with a manageable safety profile. Research Funding: None
- paclitaxel / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Anlotinib, a multitarget tyrosine kinase inhibitor, for advanced lung cancer patients: Efficacy in real-world study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3800;
Anlotinib provides more significant benefits when combining with PD1 inhibitor or chemotherapy comparing with monotherapy in patients with advanced NSCLC. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] The clinical activity and safety of anlotinib combined with anti-PD-1 antibodies in patients with advanced solid tumors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3456;
anlotinib can be administered combined with anti-PD-1 antibodies with acceptable toxicity and promising durable antitumor efficacy that warrant further testing in a randomized trial. Research Funding: Western Medicine Guiding Project of Shanghai Science and Technology Commission
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy. (Poster Board 414) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2549;
P4
Effectiveness can also be observed in patients who have failed in other targeted therapy. The adverse events are minor and can be tolerated.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor. (Poster Board 413) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2548;
P2
The phase II study shows a promising activity of anlotinib in patients with relapsed or metastatic primary malignant bone tumor and an acceptable toxicity. Research Funding: None
- Avastin (bevacizumab) / Roche, Conmana (icotinib) / Betta, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004). (Poster Board 339) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2426;
P2
The combination was well tolerated and the AEs were manageable. The follow-up time is not sufficient and the PFS and OS outcomes need further evaluation.
- [VIRTUAL] The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial. (Poster Board 259) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2335;
Based on these encouraging results, phase III trial of anlotinib plus etoposide and cisplatin/carboplatin for treatment-naive SCLC has been warranted. Research Funding: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202). (Poster Board 256) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2332;
P2
Anlotinib improved PFS and OS in advanced SCLC patients relapsed within 3 months after second-line treatment and was well tolerated. Research Funding: None
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] A phase Ib study of TQ-B2450 plus anlotinib in patients with advanced solid tumor. (Poster Board 129) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1341;
P1
12mg anlotinib plus TQ-B2450 showed an acceptable safety profile and promising response in advanced solid tumors. Research Funding: None
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Metastases: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 27, 2020
P, N=150, Not yet recruiting, Sponsor: Sun Yat-sen University
- | New P2 trial: First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC (clinicaltrials.gov) - Apr 26, 2020
P2, N=20, Not yet recruiting, Sponsor: Taizhou Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Circulating tumor DNA, Metastases: Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib (clinicaltrials.gov) - Apr 23, 2020
P2, N=240, Not yet recruiting, Sponsor: Second Affiliated Hospital of Nanchang University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: ALTER L012: Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC (clinicaltrials.gov) - Apr 15, 2020
P1, N=43, Recruiting, Sponsor: Henan Cancer Hospital
Research Funding: None Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Jan 2020 --> Oct 2020
- || AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 15, 2020
P2, N=120, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Jan 2020 --> Oct 2020 Trial completion date: Dec 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Oct 2020
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma?ESCC?. (clinicaltrials.gov) - Apr 14, 2020
P2, N=47, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Dec 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Oct 2020 Not yet recruiting --> Recruiting
- genolimzumab (CBT-501) / Apollomics
[VIRTUAL] The efficacy and safety of Geptanolimab (GB226) in patients with recurrent/metastatic/unresectable alveolar soft part sarcoma (ASPS): A multicenter, open-label, single-arm, phase 2 trial (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_320;
P2
The ORR was 33.3% (95%CI: 7.5%-70.1%) in patients with prior anlotinib therapy (n=9). Geptanolimab shows promising efficacy and acceptable safety profile for recurrent/metastatic/unresectable ASPS.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Trial primary completion date, Surgery, Metastases, Post-surgery: ALTER-H-004: Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (clinicaltrials.gov) - Apr 13, 2020
P2, N=48, Recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Geptanolimab shows promising efficacy and acceptable safety profile for recurrent/metastatic/unresectable ASPS. Not yet recruiting --> Recruiting | Initiation date: Dec 2019 --> Apr 2020 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Metastases: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 13, 2020
P3, N=648, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P4 trial, Combination therapy, Metastases: Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer (clinicaltrials.gov) - Apr 7, 2020
P4, N=37, Completed, Sponsor: Beijing Friendship Hospital
- |||| AL2846 / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2020
P1/2, N=56, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC (clinicaltrials.gov) - Apr 6, 2020
P2, N=62, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
Not yet recruiting --> Recruiting | Initiation date: Dec 2019 --> Apr 2020 | Trial primary completion date: Dec 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov) - Apr 5, 2020
P3, N=780, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Review, Journal: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. (Pubmed Central) - Apr 4, 2020
Common adverse drug reactions (ADRs) in anlotinib-treated patients included hypertension (67.4%), hand-foot syndrome (43.9%), hemoptysis (14.0%), thyroid stimulating hormone (TSH) elevation (46.6%), and corrected QT interval (QTc) prolongation (26.2%). Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy.
- | Journal: Rapid advances in research on and development of anticancer drugs in China. (Pubmed Central) - Apr 3, 2020
There are unprecedented opportunities for development of innovative drugs in China. In the future, innovative drug development in China is poised to shift from "me too" or "me better" drugs to "first-in-class" or "best-in-class" drugs.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial completion date, Trial primary completion date: Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line?ALTER-L020? (clinicaltrials.gov) - Apr 3, 2020
P4, N=103, Recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
In the future, innovative drug development in China is poised to shift from "me too" or "me better" drugs to "first-in-class" or "best-in-class" drugs. Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Nov 2021
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: ALTER-H-002: Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 3, 2020
P2, N=28, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Nov 2021 Not yet recruiting --> Recruiting
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: TQB2450-III-05: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Mar 29, 2020
P3, N=315, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- |||| AL2846 / Advenchen, Sino Biopharm
New P2 trial: A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (clinicaltrials.gov) - Mar 29, 2020
P2, N=60, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (clinicaltrials.gov) - Mar 27, 2020
P2, N=43, Recruiting, Sponsor: Yongchang Zhang
Not yet recruiting --> Recruiting Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced NSCLC： the ATHENA Study (clinicaltrials.gov) - Mar 26, 2020
P, N=70, Recruiting, Sponsor: Hunan Province Tumor Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. (Pubmed Central) - Mar 22, 2020
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Anlotinib might suppress proliferation of SS through a novel downstream GINS1-regulated network which plays a vital function in SS proliferation and also demonstrated that targeting the GINS1-regulated signal pathway could be a potential strategy for management of SS.